These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 8056282)
1. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors. Brun T; Péduzzi J; Caniça MM; Paul G; Névot P; Barthélémy M; Labia R FEMS Microbiol Lett; 1994 Jul; 120(1-2):111-7. PubMed ID: 8056282 [TBL] [Abstract][Full Text] [Related]
2. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases. Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097 [TBL] [Abstract][Full Text] [Related]
3. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544 [TBL] [Abstract][Full Text] [Related]
4. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors. Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Henquell C; Chanal C; Sirot D; Labia R; Sirot J Antimicrob Agents Chemother; 1995 Feb; 39(2):427-30. PubMed ID: 7726509 [TBL] [Abstract][Full Text] [Related]
6. Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases. Caniça MM; Barthélémy M; Gilly L; Labia R; Krishnamoorthy R; Paul G Antimicrob Agents Chemother; 1997 Feb; 41(2):374-8. PubMed ID: 9021194 [TBL] [Abstract][Full Text] [Related]
7. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192 [TBL] [Abstract][Full Text] [Related]
8. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase. Cherubin CE; Eng RH; Smith SM; Tan EN J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . Livermore DM; Seetulsingh P J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013 [TBL] [Abstract][Full Text] [Related]
10. Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors. Vedel G; Belaaouaj A; Gilly L; Labia R; Philippon A; Névot P; Paul G J Antimicrob Chemother; 1992 Oct; 30(4):449-62. PubMed ID: 1490918 [TBL] [Abstract][Full Text] [Related]
11. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Ishii Y; Ohno A; Taguchi H; Imajo S; Ishiguro M; Matsuzawa H Antimicrob Agents Chemother; 1995 Oct; 39(10):2269-75. PubMed ID: 8619581 [TBL] [Abstract][Full Text] [Related]
12. Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244. Bret L; Chaibi EB; Chanal-Claris C; Sirot D; Labia R; Sirot J Antimicrob Agents Chemother; 1997 Nov; 41(11):2547-9. PubMed ID: 9371365 [TBL] [Abstract][Full Text] [Related]
13. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Blazquez J; Baquero MR; Canton R; Alos I; Baquero F Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123 [TBL] [Abstract][Full Text] [Related]
14. TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae. Arpin C; Labia R; Dubois V; Noury P; Souquet M; Quentin C Antimicrob Agents Chemother; 2002 May; 46(5):1183-9. PubMed ID: 11959543 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276. Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468 [TBL] [Abstract][Full Text] [Related]
16. Effect of non-β-lactams on stable variants of inhibitor-resistant TEM β-lactamase in uropathogenic Escherichia coli: implication for alternative therapy. Mukherjee SK; Mandal RS; Das S; Mukherjee M J Appl Microbiol; 2018 Mar; 124(3):667-681. PubMed ID: 29247576 [TBL] [Abstract][Full Text] [Related]
17. [Detection of beta-lactamases resistant to inhibitors (IRT) by the disk diffusion method]. Romaszko JP; Bret L; Henquell C; Sirot D; Chanal C; Sirot J Pathol Biol (Paris); 1995 Apr; 43(4):306-9. PubMed ID: 7567120 [TBL] [Abstract][Full Text] [Related]
18. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060 [TBL] [Abstract][Full Text] [Related]
19. Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam. Ma L; Ishii Y; Ishiguro M; Matsuzawa H; Yamaguchi K Antimicrob Agents Chemother; 1998 May; 42(5):1181-6. PubMed ID: 9593147 [TBL] [Abstract][Full Text] [Related]